Exceeding Radiation Dose to Volume Parameters for the Proximal Airways with Stereotactic Body Radiation Therapy Is More Likely for Ultracentral Lung Tumors and Associated with Worse Outcome.
SBRT
dose constraints
lung cancer
survival
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
10 Jul 2021
10 Jul 2021
Historique:
received:
10
06
2021
revised:
01
07
2021
accepted:
07
07
2021
entrez:
24
7
2021
pubmed:
25
7
2021
medline:
25
7
2021
Statut:
epublish
Résumé
The preferred radiotherapeutic approach for central (CLT) and ultracentral (UCLT) lung tumors is unclear. We assessed the toxicity and outcomes of patients with CLT and UCLT who underwent definitive five-fraction stereotactic body radiation therapy (SBRT). We reviewed the charts of patients with either CLT or UCLT managed with SBRT from June 2010-April 2019. CLT were defined as gross tumor volume (GTV) within 2 cm of either the proximal bronchial tree, trachea, mediastinum, aorta, or spinal cord. UCLT were defined as GTV abutting any of these structures. Propensity score matching was performed for gender, performance status, and history of prior lung cancer. Within this cohort of 83 patients, 43 (51.8%) patients had UCLT. The median patient age was 73.1 years with a median follow up of 29.9 months. The two most common dose fractionation schemes were 5000 cGy (44.6%) and 5500 cGy (42.2%) in five fractions. Multivariate analysis revealed UCLT to be associated with worse overall survival (OS) (HR = 1.9,
Identifiants
pubmed: 34298677
pii: cancers13143463
doi: 10.3390/cancers13143463
pmc: PMC8305634
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NCI NIH HHS
ID : P30CA016056
Pays : United States
Références
Pharm Stat. 2011 Mar-Apr;10(2):150-61
pubmed: 20925139
Clin Lung Cancer. 2018 Sep;19(5):e803-e810
pubmed: 30007498
Lung Cancer. 2009 Oct;66(1):89-93
pubmed: 19168260
Lung Cancer. 2015 Jul;89(1):50-6
pubmed: 25997421
J Hematol Oncol. 2010 Oct 22;3:39
pubmed: 20969774
Br J Cancer. 2016 Jun 28;115(1):76-9
pubmed: 27195423
Int J Radiat Oncol Biol Phys. 2010 Jun 1;77(2):344-9
pubmed: 19765913
Lung Cancer. 2018 Jan;115:1-4
pubmed: 29290248
Clin Lung Cancer. 2020 Nov 18;:
pubmed: 33281061
Int J Radiat Biol. 2019 Mar;95(3):329-337
pubmed: 30676182
Radiother Oncol. 1998 Nov;49(2):175-83
pubmed: 10052884
Cancer Manag Res. 2019 Jan 21;11:943-953
pubmed: 30718965
Cancer Sci. 2019 Nov;110(11):3553-3564
pubmed: 31464032
Adv Radiat Oncol. 2019 Jan 24;4(2):422-428
pubmed: 31011688
J Clin Oncol. 2019 May 20;37(15):1316-1325
pubmed: 30943123
J Thorac Oncol. 2016 Jul;11(7):1081-9
pubmed: 27013408
J Thorac Oncol. 2021 Jul;16(7):1200-1210
pubmed: 33823286
J Clin Oncol. 2006 Oct 20;24(30):4833-9
pubmed: 17050868
J Thorac Oncol. 2019 Aug;14(8):1332-1342
pubmed: 31075543
Clin Lung Cancer. 2018 Jul;19(4):e529-e532
pubmed: 29759332
Int J Radiat Oncol Biol Phys. 2019 Nov 15;105(4):752-759
pubmed: 31445956
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Thorac Oncol. 2015 Apr;10(4):577-85
pubmed: 25514807
Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1077-1084
pubmed: 30513377
Ther Radiol Oncol. 2019 May;3:
pubmed: 33880444
J Radiother Pract. 2017 Jun;16(2):148-154
pubmed: 30713468
JAMA. 2010 Mar 17;303(11):1070-6
pubmed: 20233825
Radiat Oncol. 2020 Feb 27;15(1):61
pubmed: 32106868
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1168-76
pubmed: 25303891
Radiat Oncol. 2018 Apr 25;13(1):77
pubmed: 29695273
Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):132-141
pubmed: 30176275
Int J Radiat Oncol Biol Phys. 1997 Jun 1;38(3):533-40
pubmed: 9231677
Radiother Oncol. 2018 Nov;129(2):277-283
pubmed: 30049454
Pract Radiat Oncol. 2016 Mar-Apr;6(2):e27-33
pubmed: 26577006
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):677-82
pubmed: 19251380
Radiat Oncol. 2018 Apr 2;13(1):57
pubmed: 29606150
Am J Clin Oncol. 2021 Jan 1;44(1):18-23
pubmed: 33264123
Int J Radiat Oncol Biol Phys. 2020 May 1;107(1):72-78
pubmed: 31987965